TU2218

· TiumBio Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TU2218, covering 2025-03-30 to 2025-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

See pricing